Liquidia Reports Results of LIQ861 in P-III INSPIRE Trial in Patients with Pulmonary Arterial Hypertension (PAH)

Shots:

• The study involves assessing of LIQ861 in 109 patients divided in two groups of 65 prostacyclin-naive patients that were stable on ≤2 approved oral PAH therapies and 44 patients transitioning from Tyvaso (transition) with pAH
• The study resulted in median MLWHFQ score @transition and add on patients from 37 to 29 and 30 to 19, median 6MWD 395m and 408m and 428m and 449m, no serious adverse events (SAEs) related to LIQ861, safe and well-tolerated, Presented at 39th International Society for Heart & Lung Transplantation (ISHLT)
• LIQ861 is a inhaled dry powder formulation of treprostinil developed using Liquidia’s PRINT technology targeted as an alternative to current inhaled treprostinil therapy for the treatment of PAH

Click here to read full press release/ article | Ref: Liquidia | Image: Twitter